Cargando…

Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes

CD38 is a transmembrane glycoprotein that functions both as a receptor and an ectoenzyme, playing key roles in the regulation of calcium signaling and migration of immune cells to tumor microenvironments. High expression on multiple myeloma (MM) cells and limited expression on normal cells makes CD3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leleu, Xavier, Martin, Thomas, Weisel, Katja, Schjesvold, Fredrik, Iida, Shinsuke, Malavasi, Fabio, Manier, Salomon, Chang-Ki Min, Ocio, Enrique M., Pawlyn, Charlotte, Perrot, Aurore, Quach, Hang, Richter, Joshua, Spicka, Ivan, Yong, Kwee, Richardson, Paul G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463192/ https://www.ncbi.nlm.nih.gov/pubmed/35943588 http://dx.doi.org/10.1007/s00277-022-04917-5

Ejemplares similares

Difficult‐to‐treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
por: Raab, Marc S., et al.
Publicado: (2023)

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
por: Moreau, Philippe, et al.
Publicado: (2023)

P979: PATIENT-REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Moreau, Philippe, et al.
Publicado: (2023)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
por: Podar, Klaus, et al.
Publicado: (2021)

Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
por: Martin, Tom, et al.
Publicado: (2022)

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH)
por: Bahlis, Nizar J., et al.
Publicado: (2023)

PB2090: SYSTEMATIC LITERATURE REVIEW OF PROGNOSTIC FACTORS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Kumar, Shaji, et al.
Publicado: (2023)

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY
por: Schjesvold, F, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics
por: Harrison, Simon J., et al.
Publicado: (2021)

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma
por: Mikhael, Joseph, et al.
Publicado: (2020)

Current and Novel Alkylators in Multiple Myeloma
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment
por: Dimopoulos, Meletios A., et al.
Publicado: (2022)

Bone Marrow Microenvironment in Multiple Myeloma Progression
por: Manier, S., et al.
Publicado: (2012)

P960: HEALTH-RELATED QUALITY OF LIFE IN THE LOCOMMOTION STUDY OF REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Delforge, M., et al.
Publicado: (2022)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C S, et al.
Publicado: (2018)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma
por: Dimopoulos, M A, et al.
Publicado: (2014)

Selinexor in relapsed/refractory multiple myeloma
por: Richter, Joshua, et al.
Publicado: (2020)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2021)

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
por: Schjesvold, Fredrik, et al.
Publicado: (2022)

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C. S., et al.
Publicado: (2019)

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
por: Mateos, M, et al.
Publicado: (2023)

Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
por: Matsue, Kosei, et al.
Publicado: (2015)

Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
por: Bisht, Kamlesh, et al.
Publicado: (2023)

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab
por: Mikhael, Joseph, et al.
Publicado: (2021)

CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
por: Morandi, Fabio, et al.
Publicado: (2018)

Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2023)

P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study
por: Touzeau, Cyrille, et al.
Publicado: (2022)

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
por: Martin, Thomas, et al.
Publicado: (2023)

COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
por: Ludwig, Heinz, et al.
Publicado: (2021)

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
por: Richardson, Paul G., et al.
Publicado: (2021)

Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial
por: Maruyama, Dai, et al.
Publicado: (2018)

Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study
por: Martin, Thomas, et al.
Publicado: (2023)

P907: CARFILZOMIB, DEXAMETHASONE, AND DARATUMUMAB (KDD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): FRAILTY SUBGROUP ANALYSIS OF THE CANDOR STUDY
por: Quach, H., et al.
Publicado: (2022)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cfbapk8qrenr31tcq0746n49k0